Research institute
Pembrolizumab either used alone or in combination with chemotherapy was more effective than a standard cocktail of chemotherapy drugs in a study involving nearly 900 patients.
Alzheimer’s Research UK, the UK’s leading dementia research charity, has welcomed the Labour Party’s manifesto pledge to improve access to future treatments for conditions like dementia.
Progressive degeneration of dopamine-producing nerve cells in the brain leads to dopamine deficiency and ultimately to Parkinson’s disease.
Researchers have tested a new drug combination that shows promise for the treatment of several types of childhood brain cancers known as diffuse midline gliomas.
A peculiarity of autoimmune diseases is that they have many genes in common, but they develop differently.
Regenstrief Institute is investing and partnering with Care Revolution, a medical startup focused on improving care at nursing facilities, controlling costs and reducing trips to the hospital.
Shaun Grannis, M.D., M.S., an internationally recognized expert in informatics, data analytics, and biosurveillance, has been named the Regenstrief Institute’s first vice president of data and analytics.
New research is shedding light on a possible new approach to treating the rare and fatal premature aging syndrome, progeria.
Regenstrief Institute has been on the cutting edge of informatics for 50 years.
MD Anderson researchers find abundant cytokine crowds out helper T cells crucial to treatment
PRESS RELEASES